SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test ...

San Diego, California-based ResMed has received FDA 510(k) clearance for its small, portable continuous positive airway pressure (CPAP) device, the AirMini. The announcement was made during the JP ...

On Thursday, ResMed Inc (NYSE:RMD) reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04. The company reported sales of $1.224 billion, up 11%, beating ...

Home CPAP device maker Resmed is launching a small, disposable wearable to help diagnose cases of obstructive sleep apnea. The NightOwl testing device, about the size of a quarter, is worn on the user ...

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a ...

Two digital health companies focused on sleep published data this week that highlighted the efficacy of their respective platforms, bringing continued attention to the space after a CES week where ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Oct 24 (Reuters) - ResMed (RMD.N), opens new tab beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its devices used for sleep apnea treatment. Shares of the ...

NEW YORK, May 1 (Reuters) - Respiratory equipment maker ResMed Inc swung to a fiscal third-quarter profit from a year-earlier loss on lower expenses and higher sales of its devices for sleep breathing ...

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the ...

Resmed Inc ((RMD)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...